In the BioHarmony Drug Report Database
Tbo-filgrastim
Neupogen (filgrastim) is a protein pharmaceutical. Filgrastim was first approved as Neupogen on 1991-02-20. It is used to treat neutropenia in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, neoplasms, and neutropenia. It is known to target macrophage colony-stimulating factor 1 receptor and granulocyte colony-stimulating factor receptor.
Trade Name
|
Neupogen |
|---|---|
Common Name
|
filgrastim |
ChEMBL ID
|
CHEMBL1201567 |
Indication
|
hematopoietic stem cell transplantation, neoplasms, neutropenia |
Drug Class
|
Colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF) |
Image (chem structure or protein)
